Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Early Hormone Receptor-positive Breast Cancer 1Breast Neoplasms 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 69Letrozole 62Cyclophosphamide 61Paclitaxel 60pertuzumab 52Specimen Handling 52Docetaxel 50abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 33Blood Specimen Collection 33Tamoxifen 32sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Antineoplastic Agents × Breast × Clear all
NCT03591276 2020-10-23

KEYDOX

Shaare Zedek Medical Center

Phase 1/2 Recruiting
15 enrolled
Breast

Breast Neoplasms

NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡